Alaunos Therapeutics, Inc. announced early clinical findings from its ongoing TCR-T Library Phase 1/2 trial. The TCR-T Library Phase 1/2 trial is an open label, dose escalation study being conducted at The University of Texas MD Anderson Cancer Center. The trial is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers that have a matching human leukocyte antigen (HLA) and hotspot mutation pairing in Alaunos' TCR library.

The first patient dosed was diagnosed with non-small cell lung cancer with a KRAS G12D mutation, matching one of the ten TCRs within the Company's TCR library. The patient received TCR-T cells, which were produced using Sleeping Beauty at the Company's in house cGMP manufacturing facility. The patient had a confirmed objective partial response.

The Company has dosed a second patient in the study, diagnosed with colon cancer, who has been treated at the second dose level and has cleared the 28-day safety window.